Karyopharm Therapeutics | KPTI - Operating Expenses


Karyopharm Therapeutics reported $61.83M in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
AbbVie USD 10.52B 258M Sep/2026
Abbott USD 11.66B 1.2B Sep/2026
Amgen USD 5.69B 6B Sep/2026
AstraZeneca USD 11.55B 674M Sep/2026
BioCryst Pharmaceuticals USD -397.38M 517.17M Sep/2026
Bristol-Myers Squibb USD 23.4B 1.08B Sep/2026
Eli Lilly USD 10.52B 496M Jun/2026
Enanta Pharmaceuticals USD 126.59M 346.51M Dec/2025
GlaxoSmithKline GBP 6.03B 227M Sep/2026
Incyte USD 5.64B 4.67B Sep/2026
J&J USD 18.93B 1.09B Sep/2026
Karyopharm Therapeutics USD 61.83M 9.9M Mar/2026
MacroGenics USD 42.87M 21.68M Jun/2026
Merck USD 10.75B 5.02B Sep/2026
Nektar Therapeutics USD 49.12M 8.22M Mar/2026
Novartis USD 9.88B 325M Sep/2026
Novartis USD 13.19B 3.9B Sep/2026
Pfizer USD 89B 3.81B Sep/2026
Regeneron Pharmaceuticals USD 33.5B 1.79B Sep/2026
Roche Holding CHF 18.9B 2.12B Jun/2026
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Takeda JPY 981.78B 36.71B Sep/2026
Tectonic Therapeutic USD 24.22M 3.08M Jun/2026
TG Therapeutics USD 218.66M 48.54M Jun/2026
Ultragenyx Pharmaceutical USD 283M 6M Sep/2026
Xencor USD 87.82M 5.44M Jun/2026